Serum parathyroid hormone and risk of sarcopenia: a meta-analysis
Authors:
Open Access
- 3 November 2025
- journal article
- research article
- Published by Springer Nature in Journal of Orthopaedic Surgery and Research
- Vol. 20 (1) , 1-10
Abstract
Parathyroid hormone plays a key role in muscle metabolism and function, yet its precise association with sarcopenia remains controversial. This meta-analysis evaluated the relationship between serum parathyroid hormone levels and the risk of sarcopenia. We systematically searched PubMed, Embase, and Web of Science until April 2025 for observational studies on the link between parathyroid hormone levels and sarcopenia. Using random-effects models, we derived pooled odds ratios with 95% confidence intervals and conducted subgroup analyses. Sensitivity analyses were performed to ensure robustness by excluding small or low-quality studies. Study quality was assessed with modified Newcastle–Ottawa scales, and publication bias was checked using funnel plot symmetry. This meta-analysis included 11 studies involving 4,759 participants, with mean ages ranging from 57.5 to 76.4 years and 50.37% of participants being female. Our meta-analysis showed a positive association between serum parathyroid hormone levels and the risk of sarcopenia (odds ratios = 1.10, 95% confidence intervals 1.03–1.17, P < 0.001). Subgroup analyses indicated a consistently positive association across diagnostic definitions and study settings, although the effect size was greater in studies using alternative diagnostic criteria (OR = 1.94, 95% confidence intervals 1.21–3.13) and in hospital-based populations (OR = 2.19, 95% confidence intervals 1.27–3.77). Sensitivity analysis confirmed the stability of these findings, with no publication bias detected. This meta-analysis suggests a potential positive association between elevated parathyroid hormone levels and sarcopenia risk. However, given the substantial heterogeneity and the observational nature of the included studies, these findings should be interpreted with caution. Further large-scale, prospective investigations are warranted to clarify the causal relationship and to explore whether targeting parathyroid hormone could contribute to sarcopenia prevention or management.Keywords
All Related Versions
Funding Information
- Hunan Natural Science Foundation- -Outstanding Youth Foundation (2022JJ20099)
This publication has 57 references indexed in Scilit:
- Effects of hormonal changes on sarcopenia in chronic kidney disease: where are we now and what can we do?Journal of Cachexia, Sarcopenia and Muscle, 2021
- Teriparatide and exercise improve bone, skeletal muscle, and fat parameters in ovariectomized and tail-suspended ratsJournal of Bone and Mineral Metabolism, 2021
- Effects of Elevated Parathyroid Hormone Levels on Muscle Health, Postural Stability and Quality of Life in Vitamin D-Insufficient Healthy Women: A Cross-Sectional StudyCalcified Tissue International, 2019
- Phenotype of sarcopenic obesity in older individuals with a history of fallingArchives of Gerontology and Geriatrics, 2016
- Endocrine determinants of incident sarcopenia in middle-aged and elderly European menJournal of Cachexia, Sarcopenia and Muscle, 2015
- Secondary hyperparathyroidism and its relationship with sarcopenia in elderly womenArchives of Gerontology and Geriatrics, 2015
- Current perspectives on parathyroid hormone (PTH) and PTH-related protein (PTHrP) as bone anabolic therapiesBiochemical Pharmacology, 2013
- A basic introduction to fixed-effect and random-effects models for meta-analysisResearch Synthesis Methods, 2010
- Comparison of Two Methods to Detect Publication Bias in Meta-analysisJAMA, 2006
- Meta-analysis of Observational Studies in EpidemiologyA Proposal for ReportingJAMA, 2000